NCT03390504 2026-04-13THORJanssen Research & Development, LLCPhase 3 Active not recruiting629 enrolled 32 charts 1 FDA
NCT04656652 2026-03-24Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Daiichi SankyoPhase 3 Active not recruiting605 enrolled 14 charts 3 FDA
NCT05116189 2026-03-09KEYNOTE-B96Merck Sharp & Dohme LLCPhase 3 Active not recruiting643 enrolled 17 charts 3 FDA
NCT02486718 2026-02-05Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]Hoffmann-La RochePhase 3 Active not recruiting1,280 enrolled 24 charts 2 FDA
NCT04025879 2025-10-16A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerBristol-Myers SquibbPhase 3 Active not recruiting461 enrolled 18 charts 3 FDA